• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于危重症脓毒症患者治疗药物监测数据的万古霉素群体药代动力学模型。

Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients.

机构信息

University Clinical Centre of the Republic of Srpska, Dvanaest beba bb, Banja Luka 78000, Bosnia and Herzegovina; Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000, Banja Luka, Bosnia and Herzegovina.

Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Beograd, Serbia.

出版信息

J Crit Care. 2020 Feb;55:116-121. doi: 10.1016/j.jcrc.2019.10.012. Epub 2019 Nov 5.

DOI:10.1016/j.jcrc.2019.10.012
PMID:31715528
Abstract

PURPOSE

The present study aimed to establish a population pharmacokinetic model of vancomycin, including adult critically ill septic patients, with normal and impaired renal function.

MATERIALS AND METHODS

A prospective analysis of 146 concentrations from 73 adult critically ill septic patients treated with 1-h intravenous infusion of vancomycin were included in the study. A nonlinear mixed effects modeling (NONMEM) approach was applied for data analysis and evaluation of the final model. The influence of creatinine clearance calculated by the Cockcroft-Gault equation (CrCl), and other potential covariates on vancomycin clearance (CL) were evaluated.

RESULTS

The final one-compartment pharmacokinetic model includes the effect of CrCl on CL. Population pharmacokinetic values for a typical subject were estimated at 0.024 l/h for CL dependent on renal function (CLCrCl), 1.93 l/h for residual portion of CL (not dependent on renal function), and 0.511 l/kg for volume of distribution (V). According to the final model, for patients with CrCl = 120 ml/min, the median vancomycin total CL is 4.81 l/h, while CrCl-dependent fraction accounts for approximately 60% of CL.

CONCLUSIONS

The developed population vancomycin model may be used in estimating individual CL for adult critically ill septic patients, and could be applied for individualizing dosage regimens taking into account the continuous effect of CrCl.

摘要

目的

本研究旨在建立包括肾功能正常和受损的成年危重症脓毒症患者在内的万古霉素群体药代动力学模型。

材料和方法

本研究纳入了 73 例接受 1 小时静脉输注万古霉素治疗的成年危重症脓毒症患者的 146 个浓度的前瞻性分析。采用非线性混合效应建模(NONMEM)方法进行数据分析和最终模型评估。评估了 Cockcroft-Gault 方程(CrCl)计算的肌酐清除率(CrCl)和其他潜在协变量对万古霉素清除率(CL)的影响。

结果

最终的单室药代动力学模型包括 CrCl 对 CL 的影响。典型患者的群体药代动力学值估计为:肾功能依赖的 CL(CLCrCl)为 0.024 l/h,不依赖肾功能的 CL 残差部分为 1.93 l/h,分布容积(V)为 0.511 l/kg。根据最终模型,对于 CrCl=120 ml/min 的患者,万古霉素总 CL 的中位数为 4.81 l/h,而 CrCl 依赖部分约占 CL 的 60%。

结论

所开发的万古霉素群体模型可用于估计成年危重症脓毒症患者的个体 CL,并可考虑 CrCl 的持续影响来个体化剂量方案。

相似文献

1
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients.基于危重症脓毒症患者治疗药物监测数据的万古霉素群体药代动力学模型。
J Crit Care. 2020 Feb;55:116-121. doi: 10.1016/j.jcrc.2019.10.012. Epub 2019 Nov 5.
2
Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.确定危重症患者万古霉素持续输注的最佳负荷剂量和维持剂量:群体药代动力学建模和模拟以改进给药方案。
Int J Antimicrob Agents. 2019 Dec;54(6):702-708. doi: 10.1016/j.ijantimicag.2019.09.018. Epub 2019 Oct 7.
3
Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.接受持续肾脏替代治疗的重症患者美罗培南的群体药代动力学。
Clin Pharmacokinet. 2008;47(3):173-80. doi: 10.2165/00003088-200847030-00003.
4
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.重症患者万古霉素剂量:改进连续输注方案的有力方法。
Antimicrob Agents Chemother. 2011 Jun;55(6):2704-9. doi: 10.1128/AAC.01708-10. Epub 2011 Mar 14.
5
Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.危重症患者持续静静脉血液滤过期间的万古霉素清除率
Intensive Care Med. 1999 Oct;25(10):1100-4. doi: 10.1007/s001340051018.
6
Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?万古霉素群体药代动力学在脓毒症或感染性休克成人患者中的应用:目前的给药方案是否足够?
Eur J Clin Pharmacol. 2019 Sep;75(9):1219-1226. doi: 10.1007/s00228-019-02694-1. Epub 2019 Jun 1.
7
Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.重症儿童万古霉素群体药代动力学与剂量优化。
Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):539-546. doi: 10.1007/s13318-021-00695-z. Epub 2021 Jun 22.
8
Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?群体药动学模型能否指导危重症患者连续性肾脏替代治疗期间万古霉素的给药剂量?
Int J Antimicrob Agents. 2013 Jun;41(6):564-8. doi: 10.1016/j.ijantimicag.2013.01.018. Epub 2013 Mar 6.
9
Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.使用浓度-时间曲线下面积与最低抑菌浓度≥400目标评估万古霉素在晚发性新生儿败血症中的应用。
Ther Drug Monit. 2015 Dec;37(6):756-65. doi: 10.1097/FTD.0000000000000216.
10
Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.肥胖脓毒症或感染性休克患者的万古霉素药代动力学。
Pharmacotherapy. 2020 Mar;40(3):211-220. doi: 10.1002/phar.2367. Epub 2020 Feb 5.

引用本文的文献

1
Subgroup-based model selection to improve the prediction of vancomycin concentrations.基于亚组的模型选择以改善万古霉素浓度的预测。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0017425. doi: 10.1128/aac.00174-25. Epub 2025 Jul 23.
2
External Validation of a Pharmacokinetic Model Developed for Vancomycin Administration via Target-Controlled Infusion.通过目标控制输注万古霉素给药所开发的药代动力学模型的外部验证
Drug Des Devel Ther. 2025 Mar 24;19:2229-2241. doi: 10.2147/DDDT.S507377. eCollection 2025.
3
Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients.
影响万古霉素谷浓度的因素;沙特非重症监护患者的群体药代动力学模型
Drug Des Devel Ther. 2024 Dec 21;18:6185-6198. doi: 10.2147/DDDT.S496512. eCollection 2024.
4
Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review.危重症患者抗生素暴露变异性的相关危险因素:一项系统评价
Antibiotics (Basel). 2024 Aug 24;13(9):801. doi: 10.3390/antibiotics13090801.
5
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling.基于模型集成的先验模型指导精准给药的最佳药代动力学模型选择。
Clin Pharmacokinet. 2024 Oct;63(10):1449-1461. doi: 10.1007/s40262-024-01425-9. Epub 2024 Sep 27.
6
Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study.在 vvECMO 治疗期间接受高剂量利奈唑胺治疗的 COVID-19 相关 ARDS 患者的血小板减少症风险:一项观察性研究。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7747-7756. doi: 10.1007/s00210-024-03136-1. Epub 2024 May 7.
7
Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-Resistant Infection: A Comparative Study between Elderly and Adult Patients.耐甲氧西林感染中万古霉素相关肾毒性及疗效的年龄差异:老年与成年患者的比较研究
Antibiotics (Basel). 2024 Apr 3;13(4):324. doi: 10.3390/antibiotics13040324.
8
Population Pharmacokinetic Model of Linezolid and Probability of Target Attainment in Patients with COVID-19-Associated Acute Respiratory Distress Syndrome on Veno-Venous Extracorporeal Membrane Oxygenation-A Step toward Correct Dosing.利奈唑胺群体药代动力学模型及COVID-19相关急性呼吸窘迫综合征患者在静脉-静脉体外膜肺氧合治疗时达到目标浓度的概率——迈向正确给药的一步
Pharmaceutics. 2024 Feb 8;16(2):253. doi: 10.3390/pharmaceutics16020253.
9
Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment.人群药代动力学和基于模型的优化方案在苏丹肾损伤成年患者中万古霉素的剂量。
Drug Des Devel Ther. 2024 Jan 16;18:81-95. doi: 10.2147/DDDT.S432439. eCollection 2024.
10
Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.万古霉素在神经外科术后患者中的群体药代动力学模型
Front Pharmacol. 2022 Sep 26;13:1005791. doi: 10.3389/fphar.2022.1005791. eCollection 2022.